Moleculin Biotech, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $15.9M | $17.7M | $19.5M | $19.0M | $14.4M | $12.8M | $11.0M | $9.7M |
| SG&A Expense | $9.1M | $8.8M | $10.0M | $11.5M | $8.4M | $6.8M | $6.3M | $5.2M |
| Operating Income | $-25.1M | $-26.6M | $-29.6M | $-30.6M | $-23.0M | $-19.7M | $-17.5M | $-15.0M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-33.6M | $-26.0M | — | — | — | $-17.4M | $-13.4M | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $-229.0K | $0 |
| Net Income | $-33.6M | $-26.0M | $-29.8M | $-29.0M | $-15.9M | $-17.4M | $-13.2M | $-11.9M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-28.42 | $-21.02 | $-1.67 | $-1.69 | $-0.07 | $-0.20 | $-0.22 | $-0.05 |
| EPS (Diluted) | — | — | — | — | $-0.07 | $-0.20 | $-0.22 | $-0.05 |
| Shares Outstanding (Basic) | 1.2M | 1.2M | 17.8M | 17.2M | 241.9M | 103.8M | 68.6M | 256.8M |
| Shares Outstanding (Diluted) | 1.2M | 1.2M | 17.8M | 17.2M | 241.9M | 103.8M | 68.6M | 256.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |